Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Market participants continued to closely monitor developments surrounding the US-Iran conflict and the progress of the monsoon. Persistent geopolitical uncertainty, along with its potential impact on crude oil prices, kept investors cautious and limited the upside in the broader market.
Investors are also expected to track domestic inflation data, movements in crude oil prices and other global geopolitical developments for further market direction. Sector- and stock-specific activity is likely to remain driven by the ongoing earnings season. The Nifty traded near the 24,600 mark.
Realty shares jumped after declining in the past two trading sessions.
At 11:25 IST, the barometer index, the S&P BSE Sensex advanced 104.44 points or 0.13% to 78,603.61. The Nifty 50 index rose 33.25 points or 0.13% to 24,604.35.
The broader market outperformed. The BSE 150 MidCap Index rose 0.31% and the BSE 250 SmallCap Index jumped 0.42%.
The market breadth was positive. On the BSE, 2,345 shares rose and 1,728 shares fell. A total of 262 shares were unchanged.
Initial Public Offer (IPO):
Dhoot Transmission received bids for 30,59,915 shares as against 2,49,56,363 shares on offer, according to stock exchange data at 11:09 IST on 10 August 2026. The issue was subscribed 0.12 times.
The issue opened for bidding on 10 August 2026 and will close on 12 August 2026. The price band of the IPO is fixed between Rs 829 and 871 per share. An investor can bid for a minimum of 17 equity shares and multiples thereof.
Molbio Diagnostics received bids for 12,09,960 shares as against 81,58,529 shares on offer, according to stock exchange data at 11:12 IST on 10 August 2026. The issue was subscribed 0.15 times.
Technocraft Ventures received bids for 2,72,32,170 shares as against 83,17,190 shares on offer, according to stock exchange data at 11:12 IST on 10 August 2026. The issue was subscribed 3.27 times.
The issue opened for bidding on 07 August 2026 and will close on 11 August 2026. The price band of the IPO is fixed between Rs 200 and 212 per share. An investor can bid for a minimum of 70 equity shares and multiples thereof.
LEAP India received bids for 3,89,18,820 shares as against 11,49,91,735 shares on offer, according to stock exchange data at 11:12 IST on 10 August 2026. The issue was subscribed 0.34 times.
The issue opened for bidding on 07 August 2026 and will close on 11 August 2026. The price band of the IPO is fixed between Rs 151 and 159 per share. An investor can bid for a minimum of 94 equity shares and multiples thereof.
Buzzing Index:
The Nifty Realty index jumped 1.50% to 899.30. The index declined 0.07% in the past two trading sessions.
Brigade Enterprises (up 3.09%), DLF (up 1.43%), Godrej Properties (up 1.37%), Aditya Birla Real Estate (up 0.69%) and Lodha Developers (up 0.53%), Sobha (up 0.5%), Phoenix Mills (up 0.4%), Anant Raj (up 0.19%), Oberoi Realty (up 0.12%) advanced.
Stocks in Spotlight:
Gland Pharma added 1.60% after the company said that it has executed a strategic manufacturing and supply agreement (MSA) with one of the leading global pharmaceutical companies
Quality Power Electrical Equipments hit an upper limit of 5% after the company reported a 46.9% increase in adjusted consolidated net profit to Rs 54.5 crore in Q1 FY27 compared with Rs 37.1 crore in Q1 FY26. Total revenue rose 32.1% YoY to Rs 256.4 crore during the quarter.
Roto Pumps added 1.29% after the company reported a 46.82% rise in consolidated net profit to Rs 9.25 crore in the quarter ended 30 June 2026, compared with Rs 6.30 crore posted in the corresponding quarter last year. Revenue from operations increased 14.75% YoY to Rs 75.60 crore in the quarter ended 30 June 2026.
Global Markets:
Asian markets mostly advanced on Monday after a soft U.S. jobs report pared the risk of a near-term rise in borrowing costs, though a lack of progress in Gulf peace talks saw oil prices creep higher.
Iran said on Sunday that a deal with Oman defining new shipping lanes in the Strait of Hormuz was in its final stages but reiterated that the waterway would only reopen once the United States met other conditions.
Brent crude rises as shipping through the vital waterway remained at a trickle, while U.S. crude rose 0.79% to $78.80 a barrel.
Meanwhile, the Bank of Japan policy makers have warned of mounting inflation risks that could require a nimble, faster-than-expected pace of interest rate increases, a summary of opinions at their July meeting showed, boosting the case for a September hike.
Last week, U.S. stocks advanced on Friday, with the S&P closing at a record high to cap off a strong week of gains for the major indexes, after data showed the U.S. economy unexpectedly shed jobs last month and dampened expectations the Federal Reserve would raise interest rates at its September meeting.
The Dow Jones Industrial Average rose 151.83 points, or 0.28%, to 54,036.93, the S&P 500 gained 47.68 points, or 0.62%, to 7,757.64 and the Nasdaq Composite gained 342.26 points, or 1.30%, to 26,690.62.
The Labor Department said nonfarm payrolls decreased by 23,000 jobs last month, well below the widely reported estimate that called for an increase of 80,000 jobs. Previously reported job gains for the prior two months were also revised sharply lower, while the unemployment rate fell to 4.1% last month from 4.2% in June due to workers leaving the labor force.
Market expectations for a rate hike from the Fed at its next meeting dropped to about 44%, according to CME FedWatch down from 55% in the prior session and 67% a week ago.
Gland Pharma said that it has entered into a five-year manufacturing and supply agreement with a leading global pharmaceutical company for the technology transfer and development of 55 sterile injectable products.
The agreement covers the manufacturing and supply of oncology and non-oncology products across multiple injectable formats.
The portfolio includes products in vial, lyophilized vial, ampoule and pre-filled syringe formats, covering both conventional and complex injectables.
The agreement spans three manufacturing sites and is expected to generate annualised revenue of $90–100 million, with revenue contribution expected to commence from CY29.
The company also has scope to add more products and undertake technology-transfer activities under the partnership, which could increase the eventual revenue opportunity.
Srinivas Sadu, executive chairman, Gland Pharma, said: 'We are pleased to enter into this strategic collaboration.
The partnership highlights the confidence global pharmaceutical companies place in Gland Pharma's development, technology transfer, manufacturing, and supply capabilities.
The agreement provides meaningful long-term revenue visibility, supports expansion of our CDMO business, and creates a strong foundation for future growth.'
Gland Pharma is a Hyderabad-based pharmaceutical company focused on generic injectables and ophthalmics. It operates in more than 60 countries under a business-to-business model and offers a broad portfolio of sterile injectable products, including vials, ampoules, pre-filled syringes, lyophilized vials, infusions, oncology and ophthalmic solutions.
On a consolidated basis, Gland Pharma's net profit surged 96.57% to Rs 366.68 crore while net sales rose 22.31% to Rs 1742.79 crore in Q4 March 2026 over Q4 March 2025.
Gland Pharma and Neuland Laboratories today announced a long-term strategic CDMO partnership.
Under the partnership Gland will establish a sterile manufacturing suite for Active Pharmaceutical Ingredients (APIs) pertaining to microparticle depot products. The collaboration combines Neuland's Complex API development and manufacturing capabilities including deep expertise in complex chemistry, process development, custom manufacturing having a strong track record of serving global innovator and generic pharmaceutical companies; with Gland Pharma's global sterile manufacturing expertise and strong regulatory compliance track record, to serve growing worldwide demand for sterile APIs used in microparticle depot products and other complex sterile APIs.
Under the collaboration, Gland Pharma will expand its existing sterile manufacturing infrastructure through an additional dedicated suite at its JNPC facility at Visakhapatnam to support Neuland for its growing demand of sterile APIs. The facility will be constructed and operated to cGMP, USFDA and EU standards, and will be backed by Gland Pharma's proven aseptic manufacturing expertise. Together, the companies will offer an integrated CDMO solution encompassing development, scale-up, regulatory support and commercial manufacturing of sterile APIs. The suite will be designed to add approximately 1400 kg of annual capacity, providing manufacturing flexibility across multiple sterile products while supporting future growth.
The approved product is bioequivalent and therapeutically equivalent to Merck Sharp & Dohme's BRIDION Injection. It is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.
The company said it has commercially launched the product in the U.S. on the first day of approval through its marketing partner.
According to IQVIA, Sugammadex Injection recorded U.S. sales of about $1.6 billion during the 12 months ended April 2026, highlighting a sizeable market opportunity.
Gland Pharma (Gland or Company), a generic injectable & ophthalmic focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), BRIDION® Injection of Merck Sharp & Dohme LLC.
The Product is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.
Gland Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 2510.4, up 1.92% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.16% on the day, quoting at 24468.6. The Sensex is at 78452.78, up 0.21%. Gland Pharma Ltd has gained around 11.68% in last one month.
Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 6.86% in last one month and is currently quoting at 25866.25, down 0.24% on the day. The volume in the stock stood at 6.18 lakh shares today, compared to the daily average of 8.44 lakh shares in last one month.
The PE of the stock is 30.83 based on TTM earnings ending March 26.
Consumer durables shares extend losses for a third consecutive session.
At 10:25 IST, the barometer index, the S&P BSE Sensex declined 832.12 points or 1.10% to 74,413.21 The Nifty 50 index dropped 261.20 points or 1.10% to 23,382.30.
The broader market underperformed the frontline indices. The BSE 150 MidCap Index tumbled 1.66% and the BSE 250 SmallCap Index dropped 2.57%.
The market breadth was negative. On the BSE, 764 shares rose and 3,102 shares fell. A total of 204 shares were unchanged.
In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 96.2300 compared with its previous close of 95.8100. It also touched an all-time intraday low of 96.25 today.
In the commodities market, Brent crude for July 2026 settlement rose $1.83 cents or 1.67% to $111.09 a barrel.
Earnings to Watch:
Indian Oil Corporation(down 2.42%), Afcons Infrastructure(down 6.87%), Ola Electric Mobility(down 3.17%), Apollo Micro Systems(down 2.16%), Indraprastha Gas(down 1.22%), JSW Cement(down 1.95%), Puravankara(down 1.90%), Sun Pharma Advanced Research Company(down 2.26%), Strides Pharma Science(down 1.81%), Baazar Style Retail (down 5.01%) and Zydus Wellness(down 2.94%) will announce their quarterly earnings today.
The Nifty consumer durables index tumbled 3.34% to 34,366.50. The index fell 3.42% in the two consecutive trading sessions.
Amber Enterprises India (down 13.68%), PG Electroplast (down 5.56%), Blue Star (down 3.8%), Kalyan Jewellers India (down 3.41%), Crompton Greaves Consumer Electricals (down 2.86%), LG Electronics India (down 2.84%), Dixon Technologies (India) (down 2.4%), Havells India (down 2.38%), Bata India (down 2.27%) and Titan Company (down 2.05%) tumbled.
Gland Pharma surged 12.47% after the pharma company has reported 96.62% increase in consolidated net profit to Rs 366.7 crore on a 22.31% rise in net sales to Rs 1,742.80 crore in Q4 FY26 over Q4 FY25.
NCC slipped 5.22% after the company reported an 18.8% drop in consolidated net profit to Rs 206.02 crore in Q4 FY26, compared to Rs 253.82 crore recorded in Q4 FY25.